Jan. 24, 2012 - Lucigen has been awarded a $187,000 grant from the Michael J. Fox Foundation for Parkinson’s Research for the study of LRRK2, a protein found throughout the brain. Excessive activity of LRRK2 has been shown to be associated with Parkinson’s disease (PD). For this reason, many PD researchers are interested in the response of LRRK2 to a variety of

compounds. Small chemical compounds that inhibit this enzyme may be helpful in understanding the mechanics of the disease. More importantly, these compounds may lead to drugs that provide effective treatments for PD. The goal of the current grant is to develop a sensitive, highthroughput, inexpensive method to screen thousands of compounds for the inhibition of LRRK2.

"This grant enables Lucigen to utilize our core strengths in protein engineering, along with a proprietary fluorescent protein previously isolated by Lucigen,in order to advance medical research into a devastating disease. As our population ages, we will only see more cases of Parkinson’s. We are proud to join the Michael J. Fox Foundation in the fight against this disease,” states David Mead, CEO. As part of this grant, Lucigen has added several new research positions at the Company.

Located in Middleton, WI, Lucigen delivers advanced molecular biology products and services to life scientists by inventing solutions to the most difficult problems in DNA cloning, amplification, and protein expression. With a focus on simplifying genomic research, Lucigen offers a wide selection of cloning kits, competent cells, and enzymes that enable scientists to quickly and easily complete even the most challenging molecular biology experiments. For more information about the firm and products, call 888-575-9695, email Lucigen@lucigen.com, or visit our website at www.lucigen.com.

For further information, please contact:

David Mead

Lucigen Corporation

2120 W. Greenview Drive

Middleton, WI53562

Phone: 608-831-9011

FAX: 608-831-9012

Email: dmead@lucigen.com